RecruitingPhase 4NCT07634484

A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

A Post-Marketing Clinical Trial of Pemafibrate in Patients With Hypercholesterolemia and Inadequate Response to Statins-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial

Sponsor

Kowa Company, Ltd.

Enrollment

120 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Hypercholesterolemia

Summary

To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Pemafibrate 0.2 mg/day, a drug called Pemafibrate 0.4 mg/day, and others for people with hypercholesterolemia. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPemafibrate 0.2 mg/day

Administered orally once daily

DRUGPemafibrate 0.4 mg/day

Administered orally once daily

DRUGPlacebo

Administered orally once daily

Locations(10)

NTT Medical Center Sapporo

Hokkaido, Japan

Ami Higashi Clinic

Ibaraki, Japan

Olive Takamatsu Medical Clinic

Kagawa, Japan

Medical Corporation Shintokai Yokohama Minoru Clinic

Kanagawa, Japan

Medical Corporation Heishinkai OCROM Clinic

Osaka, Japan

Hirose Clinic

Saitama, Japan

Medical Corporation Yukeikai Asano Internal Medicine Clinic

Saitama, Japan

Medical Corporation Asbo Tokyo Asbo Clinic

Tokyo, Japan

Medical Corporation Heishinkai ToCROM Clinic

Tokyo, Japan

Shimokitazawa Tomo Clinic

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07634484

Related Trials

Causes and Natural History of Dyslipidemias

NCT003537821 location

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT0747770434 locations

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT0645177016 locations

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

NCT074045531 location

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

NCT075241011 location